SRZN

Surrozen Inc

SRZN, USA

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

https://www.surrozen.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SRZN
stock
SRZN

Surrozen (NASDAQ:SRZN) Is In A Good Position To Deliver On Growth Plans 富途牛牛

Read more →
SRZN
stock
SRZN

Major Stakeholders Double Down on Surrozen Stock! TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$36.6667

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-8.96

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

304.67 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-76.18 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-922.08 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 54.49% of the total shares of Surrozen Inc

1.

StemPoint Capital LP

(8.0106%)

since

2025/06/30

2.

VR Adviser, LLC

(7.3851%)

since

2025/06/30

3.

RA Capital Management, LLC

(7.0315%)

since

2025/06/30

4.

5AM Venture Management, LLC

(3.6171%)

since

2025/06/30

5.

Stonepine Capital Management Llc

(3.5708%)

since

2025/06/30

6.

Vivo Capital, LLC

(3.0337%)

since

2025/06/30

7.

Samsara BioCapital, LLC

(2.8167%)

since

2025/06/30

8.

Nantahala Capital Management, LLC

(2.6782%)

since

2025/06/30

9.

Vanguard Group Inc

(2.5547%)

since

2025/06/30

10.

Longwood Capital Partners LLC

(1.9836%)

since

2025/06/30

11.

BRAIDWELL LP

(1.6335%)

since

2025/06/30

12.

Regents Of The University Of California

(1.5543%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(1.1854%)

since

2025/07/31

14.

Adage Capital Partners Gp LLC

(1.0344%)

since

2025/06/30

15.

Euclidean Capital LLC

(1.0232%)

since

2025/06/30

16.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8769%)

since

2025/07/31

17.

Driehaus Capital Management LLC

(0.7884%)

since

2025/06/30

18.

Armistice Capital, LLC

(0.7001%)

since

2025/06/30

20.

Board of Ttees Leland Stanford Jr Univ

(0.6083%)

since

2025/06/30

22.

Morgan Stanley - Brokerage Accounts

(0.4056%)

since

2025/06/30

23.

iShares Micro-Cap ETF

(0.1563%)

since

2025/08/31

24.

Fidelity Extended Market Index

(0.1435%)

since

2025/07/31

25.

Fidelity Series Total Market Index

(0.1008%)

since

2025/07/31

26.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.062%)

since

2025/07/31

27.

Fidelity Total Market Index

(0.0541%)

since

2025/07/31

28.

Spartan Total Market Index Pool G

(0.0413%)

since

2025/07/31

29.

NT Ext Equity Mkt Idx Fd - L

(0.038%)

since

2025/06/30

30.

Northern Trust Extended Eq Market Idx

(0.038%)

since

2025/06/30

31.

Spartan Extended Market Index Pool F

(0.0326%)

since

2025/07/31

32.

Fidelity Nasdaq Composite Index

(0.0323%)

since

2025/07/31

33.

Extended Equity Market Fund K

(0.0238%)

since

2025/06/30

34.

NT Ext Equity Mkt Idx Fd - NL

(0.0141%)

since

2025/06/30

35.

1290 VT Micro Cap K

(0.0132%)

since

2025/07/31

36.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0109%)

since

2025/06/30

37.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0107%)

since

2025/06/30

38.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0091%)

since

2024/12/31

39.

State St US Extended Mkt Indx NL Cl C

(0.0071%)

since

2025/08/31

40.

Vanguard U.S. Eq Idx £ Acc

(0.005%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-3.6046

EPS Estimate

-1.17

EPS Difference

-2.4346

Surprise Percent

-208.0855%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.